Spartan FRX Project Reproducibility Study

This study has been completed.
Sponsor:
Collaborators:
Children's Hospital of Eastern Ontario
Ottawa Hospital Research Institute
Mount Sinai Hospital, Canada
Information provided by (Responsible Party):
Spartan Bioscience Inc.
ClinicalTrials.gov Identifier:
NCT01676298
First received: August 28, 2012
Last updated: December 3, 2012
Last verified: December 2012
  Purpose

The Spartan FRX CYP2C19 Test System (hereafter referred to as the 'FRX System') is a qualitative in vitro diagnostic test for the identification of a patient's CYP2C19 *2, *3 and *17 genotypes from genomic DNA obtained from buccal swab samples. The objective of the study is to evaluate the performance of the FRX System under multivariate conditions including different days, sites, operators and systems.


Condition Intervention
Analytical Reproducibility of a Medical Device
Device: Spartan FRX CYP2C19 Test System

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Study of the Analytical Reproducibility of the Spartan FRX CYP2C19 *2,*3 and *17 Genotyping System.

Further study details as provided by Spartan Bioscience Inc.:

Primary Outcome Measures:
  • Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System. [ Time Frame: After second pass result is complete (~3h) ] [ Designated as safety issue: No ]

    Reproducibility was calculated as a percentage of the correct calls over the total calls made for each genotype group. All calls were made using the Spartan FRX CYP2C19 genotyping diagnostic system.

    All data analyses was qualitative, based on the genotype calls determined by the FRX system (using on-board automated data analysis). A printed result listing the genotype call for each SNP was generated by the FRX system at the end of each run. If the result of a test is "Inconclusive" for one or more SNPs, the test were immediately repeated for the corresponding SNP(s) only, per the instructions for use. Results are reported based on both first-pass and second-pass (i.e. repeated test). For both the first-pass and second-pass results, 1-sided 95% confidence lower limits were calculated using the score method for the % correct calls (i.e. % agreement).



Enrollment: 8
Study Start Date: August 2012
Study Completion Date: November 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Detailed Description:

The FRX system is comprised of hardware and consumable components. The hardware components of the system include an Analyzer (thermal cycler with fluorescence detection capability), a notebook computer and a printer. The consumable component of the FRX system is a sample collection kit. Each kit contains a buccal swab (used to collect the patient sample) and a tube containing the reagents required for genomic DNA extraction and PCR (polymerase chain reaction) amplification stages of the test.

The Spartan FRX System is capable of detecting three CYP2C19 SNPs(single nucleotide polymorphism) (*2, *3, *17) in each test performed. An individual sample collection kit is required for each SNP tested; therefore three sample collection kits are required for each test performed on the system.

To perform a test, the user collects three buccal samples from the patient and then inserts a sample into each of the three reagent tubes (one for each of the CYP2C19 loci *2, *3 and *17). The reagent tubes are placed into the Analyzer and the FRX system automates the processes of DNA extraction, PCR amplification, fluorescent signal detection and data analysis. The system provides the user with a printed result listing the patient genotypes at the *2, *3 and *17 loci.

The objective of the study is to evaluate the performance of the FRX System under multivariate conditions. Specifically, the following variables will be included in the study:

  • Test site - x3
  • Operator - x6 (2 per site)
  • Day - x15 (5 non-consecutive days per site)
  • FRX System - x16

Test performance is defined as the number of correct genotype calls, expressed as a percentage of the total number of tests performed on the system.

For both the first-pass and second-pass results, 1-sided 95% confidence lower limits will be calculated using the score method for the % correct calls (i.e. % agreement).

Genotype results from the FRX system will be compared with results of DNA sequencing. The result of the FRX System test will be determined to be correct if the genotype calls for all three SNPs are identical to the genotypes determined by DNA sequencing for that sample/individual.

Results of the Reproducibility Study will be acceptable if the lower bound of a 1-sided 95% confidence limit of the total correct call rate per genotype is greater than or equal to 95%, based on second-pass results.

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

8 Individuals with predetermined CYP2C19 *2,*3 and *17 genotypes

Criteria

Inclusion Criteria:

  • Above 16 years of age
  • Must have required genotype

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01676298

Locations
Canada, Ontario
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada, K1H 8L6
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
Mount Sinai Services
Toronto, Ontario, Canada, M5G 1Z5
Sponsors and Collaborators
Spartan Bioscience Inc.
Children's Hospital of Eastern Ontario
Ottawa Hospital Research Institute
Mount Sinai Hospital, Canada
Investigators
Principal Investigator: Chris JE Harder, PhD Spartan Bioscience
Principal Investigator: Azar Azad, PhD Mount Sinai Hospital, New York
Principal Investigator: Marc Desjardins, PhD Ottawa Hosptial Research Institute
Principal Investigator: Jean McGowan-Jordan, PhD Children's Hospital of Eastern Ontario
  More Information

No publications provided

Responsible Party: Spartan Bioscience Inc.
ClinicalTrials.gov Identifier: NCT01676298     History of Changes
Other Study ID Numbers: 01001686
Study First Received: August 28, 2012
Results First Received: November 6, 2012
Last Updated: December 3, 2012
Health Authority: Canada: Spartan Bioscience, Inc.

Keywords provided by Spartan Bioscience Inc.:
Cyp2C19
Genotyping
Spartan
Reproducibility

ClinicalTrials.gov processed this record on August 21, 2014